Erleada™
Drug - Erleada™ (apalutamide) [Janssen Products, LP]
December 2018
Therapeutic area - Antineoplastic - Antiandrogenic Agents
Initial approval criteria
- Patient has NON-metastatic castration-resistant prostate cancer (nmCRPC) AND
- Patient is at least 18 years old AND
- Patient will receive a gonadotropin-releasing hormone (GnRH)-analog or has had a bilateral orchiectomy
- Initial approval is for 6 months
Renewal criteria
- Patient continues to meet the above criteria AND
- Tumor response with stabilization of disease or decrease in size of tumor or tumor spread AND
- Absence of unacceptable toxicity from the drug
- Renewal approval is for 6 months
Quantity limits
Questions?
MHCP Provider Call Center 651-431-2700 or 800-366-5411
